Length of study participation:

• About 55 to 56 weeks

​

Number of study visits:

• 8 to 12 visits

​

Follow-up

• Telephone call

​

The World Health Organization estimates that 65 million people worldwide have moderate to severe COPD. COPD is a major cause of disability and is expected to become the leading cause of death globally within the next two decades.

 

There is no cure for COPD. There are treatments available for doctors to prescribe, including treatments called maintenance therapies to help maintain regular breathing. Doctors may prescribe one of these maintenance therapies, or they may prescribe a combination therapy of 2 or 3. However, even with the combination of all 3 therapies (called “triple therapy”), some people still have COPD symptoms or experience COPD exacerbations, which can result in a hospital admission. 

​

These research studies will assess whether new investigational therapies may reduce the occurrence of COPD exacerbations. The investigational therapies will be compared to other study treatments, such as a combination of 2 therapies, a marketed drug, or a placebo. A placebo looks like a drug but does not contain any actual medication. Placebos help to make sure that changes seen during a study are due to the investigational drug or another active medication and not another reason.